291-Prognostic ctDNA Monitoring in Resectable NSCLC
This article details a study focused on using longitudinal ultrasensitive circulating tumor DNA (ctDNA) monitoring to improve risk prediction and management for patients with non-small cell lung cancer (NSCLC). The research, based on the TRACERx study cohort, leverages a highly sensitive, tumor-informed ctDNA assay to detect molecular residual disease (MRD) both before and after surgery. Findings indicate that ctDNA detection levels, particularly those below 80 parts per million (ppm), are crucial for stratifying patient prognosis and identifying an intermediate-risk group. Furthermore, the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.